Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00108095
Status:
COMPLETED
Last Update Posted:
2017-01-20
First Post:
2005-04-13
Brief Title:
A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Dose-ranging Parallel Group Phase II Study to Evaluate the Safety Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist GW679769 When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting PONV and Post-discharge Nausea and Vomiting PDNV in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is looking at a range of doses of this NK-1 receptor antagonist drug for both safety and effectiveness in prevention PONV
Detailed Description:
A Multicenter Randomized Double-Blind Placebo-Controlled Dose-Ranging Parallel Group Phase II Study to Evaluate the Safety Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist GW67969 When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-Operative Nausea and Vomiting PONV and Post-Discharge Nausea and Vomiting PDNV in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None